Analysts expect Bluejay Diagnostics to report zero revenue for Q2 2026 as the company remains in a pre-commercial development phase, with EPS projected at a loss of approximately $1.50. The stock currently trades around $1.32, with limited official analyst price targets following a period of extreme volatility and reverse stock splits.
Investors are almost exclusively focused on the regulatory path for the Symphony IL-6 test, particularly following the successful completion of the 750-patient SYMON-II clinical study enrollment in July 2026.
The upcoming report is expected to provide critical updates on the timeline for a formal FDA 510(k) submission and the company's cash runway after recent private placements. Management's guidance on potential commercial launch dates and distribution partnerships for the Symphony platform will be the primary drivers of market sentiment.